Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allied Healthcare Group Ltd Announces No Calcification From Phase II Cardiocel Patients After Five Years


Tuesday, 24 Sep 2013 07:12pm EDT 

Allied Healthcare Group Ltd announced updated patient data from its ongoing Phase II extension study for CardioCel, its lead regenerative tissue product, which showed continued evidence of the long-term benefits of CardioCel for patients, including no sign of calcification at the site of repair. As part of the study, five patients have been monitored over a five year period post-surgery, with the results showing no signs of calcification in these patients. In addition six patients have progressed beyond four years, and eight beyond three years, all showing no signs of calcification in ongoing post-surgical monitoring. Patients will continue to be monitored. The original Phase II study met its primary and secondary endpoints of 30 day survival post-surgery. Around 20 patients have continued to be monitored in an extension study to explore the longer term benefits of CardioCel for these patients. Patients in the study were aged from two months to 14 years old. 

Company Quote

0.115
0.0050 +4.55%
24 Dec 2014